text: Yo, check it out, I'm 'bout to drop some knowledge,
  Talkin' 'bout high-dose chemotherapy in the college.
  For relapsed/refractory germ cell tumors, it's the cure,
  But it's complex, so let's explore.
  
  We evaluated blood-based systemic inflammatory indexes,
  See if they relate to outcomes, no hexes.
  GCT patients gettin' salvage treatment with HDCT,
  Lookin' for prognostic factors, can you see?
  
  Baseline characteristics and ratios we collected,
  Neutrophil-to-lymphocyte, platelet-to-lymphocyte affected.
  Systemic immune-inflammation index on the plate,
  62 patients, let's evaluate.
  
  NLR, PLR, and SII, inflammatory markers in the game,
  See if they correlate with HDCT's fame.
  Overall survival, progression-free survival too,
  Let's see if these markers give us a clue.
  
  Used the receiver operating curve to find the best cutoff,
  NLR ≥3.3, SII ≥844,000, that's enough.
  Patients with these markers had shorter PFS,
  Inferior OS, it's a real mess.
  
  Multivariable analysis, let's break it down,
  Inflammatory markers, IPFSG, age, previous line in town.
  NLR ≥3.3 and SII ≥844,000, they stand tall,
  Independently associated with shorter PFS and OS, that's all.
  
  Not just that, these markers relate to response,
  To HDCT, it's like a dance, no time to be on the fence.
  Associatin' IPFSG prognostic score with markers in sight,
  Gives us more info, helps doctors make it right.
  
  So there you have it, the study's conclusion,
  Inflammatory markers and HDCT fusion.
  Improvin' prognosis, personalized decisions in the mix,
  Rap style, droppin' knowledge, that's how we fix.